Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC). J of Skin. 2025;9(6):s689. doi:10.25251/cpgrax68